CR20220215A - Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 - Google Patents
Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1Info
- Publication number
- CR20220215A CR20220215A CR20220215A CR20220215A CR20220215A CR 20220215 A CR20220215 A CR 20220215A CR 20220215 A CR20220215 A CR 20220215A CR 20220215 A CR20220215 A CR 20220215A CR 20220215 A CR20220215 A CR 20220215A
- Authority
- CR
- Costa Rica
- Prior art keywords
- heteroaryl
- diseases
- treatment
- biphenyl amides
- biphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Abstract
Se proporcionan compuestos que son útiles como inmunomoduladores. Los compuestos tienen la Fórmula (I) incluidos estereoisómeros y sales farmacéuticamente aceptables de estos, donde R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 y n son como se definen en el presente documento. Además se describen métodos relacionados con la preparación y el uso de dichos compuestos, así como las composiciones farmacéuticas que comprenden dichos compuestos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915779P | 2019-10-16 | 2019-10-16 | |
| US202063042796P | 2020-06-23 | 2020-06-23 | |
| US202063057460P | 2020-07-28 | 2020-07-28 | |
| PCT/US2020/055672 WO2021076691A1 (en) | 2019-10-16 | 2020-10-15 | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220215A true CR20220215A (es) | 2022-09-14 |
Family
ID=75538873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220215A CR20220215A (es) | 2019-10-16 | 2020-10-15 | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11713307B2 (es) |
| EP (1) | EP4045036A4 (es) |
| JP (1) | JP2022551973A (es) |
| KR (1) | KR20220084119A (es) |
| CN (1) | CN114585359A (es) |
| AU (1) | AU2020368393A1 (es) |
| BR (1) | BR112022006018A2 (es) |
| CA (1) | CA3152329A1 (es) |
| CL (1) | CL2022000956A1 (es) |
| CO (1) | CO2022004723A2 (es) |
| CR (1) | CR20220215A (es) |
| EC (1) | ECSP22038478A (es) |
| IL (1) | IL291642A (es) |
| MX (1) | MX2022004451A (es) |
| PE (1) | PE20221445A1 (es) |
| TW (1) | TW202128651A (es) |
| WO (1) | WO2021076691A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019165043A2 (en) | 2018-02-22 | 2019-08-29 | Chemocentryx, Inc. | Indane-amines as pd-l1 antagonists |
| WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
| AU2020368392A1 (en) | 2019-10-16 | 2022-04-21 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| TW202216694A (zh) * | 2020-06-23 | 2022-05-01 | 美商卡默森屈有限公司 | 使用雜芳基-聯苯醯胺衍生物治療癌症之方法 |
| WO2022266236A1 (en) * | 2021-06-18 | 2022-12-22 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| CN115010658B (zh) * | 2022-05-11 | 2023-06-27 | 南方医科大学 | 一种化合物及其制备方法与应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2402319B1 (en) | 2006-03-31 | 2017-08-30 | Novartis AG | DGAT Inhibitors |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| PL2780338T3 (pl) | 2011-11-14 | 2017-04-28 | Ignyta, Inc. | Pochodne uracylu jako inhibitory kinaz AXL i c-MET |
| WO2013085802A1 (en) | 2011-12-06 | 2013-06-13 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| CA2923184A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP2016532711A (ja) | 2013-09-06 | 2016-10-20 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | 免疫調節剤としての１，３，４−オキサジアゾール及び１，３，４−チアジアゾールの誘導体 |
| PL3363790T3 (pl) | 2013-09-06 | 2020-07-27 | Aurigene Discovery Technologies Limited | Pochodne 1,2,4-oksadiazolu jako immunomodulatory |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US20180118718A1 (en) | 2015-05-13 | 2018-05-03 | Selvita S.A. | Substituted Quinoxaline Derivatives |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| TWI763641B (zh) | 2015-11-19 | 2022-05-11 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| TWI767896B (zh) | 2015-12-22 | 2022-06-21 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| US20170320875A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN109153626B (zh) | 2016-05-23 | 2022-06-03 | 天津红日药业股份有限公司 | 2-羟基-4-(2，3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法 |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AU2017281285C1 (en) | 2016-06-20 | 2022-05-12 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| KR102401963B1 (ko) | 2016-06-27 | 2022-05-25 | 케모센트릭스, 인크. | 면역조절제 화합물 |
| JP6994496B2 (ja) | 2016-07-05 | 2022-01-14 | グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド | 芳香族アセチレンまたは芳香族エチレン系化合物、その中間体、製造方法、薬物組成物および使用 |
| CA3029991A1 (en) | 2016-07-08 | 2018-01-11 | Bristol-Myers Squibb Company | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
| US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| TW201823199A (zh) | 2016-09-02 | 2018-07-01 | 美商北極星藥品公司 | 免疫檢查點抑制劑、組成物及其方法 |
| KR102599339B1 (ko) | 2016-12-20 | 2023-11-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 화합물 |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| TWI808955B (zh) * | 2016-12-22 | 2023-07-21 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| SG10202106743QA (en) | 2016-12-22 | 2021-08-30 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| MA47120A (fr) * | 2016-12-22 | 2021-04-28 | Incyte Corp | Dérivés pyridine utilisés en tant qu'immunomodulateurs |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN106674136B (zh) | 2016-12-23 | 2019-07-02 | 中国医科大学 | 嘧啶类抗肿瘤化合物及其制备方法 |
| WO2018121560A1 (zh) | 2016-12-29 | 2018-07-05 | 深圳微芯生物科技有限责任公司 | 脲类化合物、其制备方法及其应用 |
| CN108395443B (zh) | 2017-02-04 | 2021-05-04 | 广州丹康医药生物有限公司 | 抑制程序性死亡受体配体1的环状化合物及其用途 |
| JP7150745B2 (ja) | 2017-03-27 | 2022-10-11 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤としての置換イソキノリン誘導体 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN108794422B (zh) | 2017-04-26 | 2022-07-01 | 南京圣和药业股份有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| CN108863963B (zh) | 2017-05-08 | 2022-05-27 | 南京圣和药物研发有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| CN109400522B (zh) | 2017-08-18 | 2023-04-28 | 上海轶诺药业有限公司 | 一种具有pd-l1抑制活性的化合物、其制备方法及用途 |
| KR20200058506A (ko) | 2017-10-03 | 2020-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| CN109665968B (zh) | 2017-10-16 | 2022-02-22 | 四川科伦博泰生物医药股份有限公司 | 并环化合物及其制备方法和用途 |
| CN109678796B (zh) | 2017-10-19 | 2023-01-10 | 上海长森药业有限公司 | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 |
| CN109721527B (zh) | 2017-10-27 | 2024-03-12 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| WO2019120297A1 (zh) | 2017-12-22 | 2019-06-27 | 上海海雁医药科技有限公司 | 免疫调节剂及其制法与医药上的用途 |
| CN109988144A (zh) | 2017-12-29 | 2019-07-09 | 广州再极医药科技有限公司 | 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用 |
| CN111868061A (zh) | 2018-01-23 | 2020-10-30 | 百时美施贵宝公司 | 用作免疫调节剂的2,8-二酰基-2,8-二氮杂螺[5.5]十一烷化合物 |
| JP7033343B2 (ja) | 2018-02-05 | 2022-03-10 | アビスコ セラピューティクス カンパニー リミテッド | バイアリール誘導体、その製造方法および薬学上の使用 |
| EP4227302A1 (en) | 2018-02-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN112041312A (zh) | 2018-03-01 | 2020-12-04 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
| CN111788193B (zh) | 2018-03-13 | 2023-04-04 | 广东东阳光药业有限公司 | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 |
| WO2019175897A1 (en) | 2018-03-13 | 2019-09-19 | Jubilant Biosys Limited | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| ES2940750T3 (es) | 2018-03-30 | 2023-05-11 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| JP2021520342A (ja) | 2018-04-03 | 2021-08-19 | ベータ ファーマシューティカルズ カンパニー リミテッド | 免疫調節物質、組成物及びそれらの方法 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| PE20211918A1 (es) | 2018-05-11 | 2021-09-28 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridin como inmunomoduladores de pd-l1 |
| CN111886219B (zh) | 2018-07-11 | 2023-04-25 | 上海和誉生物医药科技有限公司 | 免疫抑制剂及其制备方法和在药学上的应用 |
| US20220119411A1 (en) | 2018-07-12 | 2022-04-21 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
| WO2020015716A1 (en) | 2018-07-19 | 2020-01-23 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| WO2020015717A1 (en) | 2018-07-19 | 2020-01-23 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| US20210347785A1 (en) | 2018-08-01 | 2021-11-11 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Preparation and application of aromatic compound having immunoregulatory function |
| CN109336857A (zh) | 2018-11-13 | 2019-02-15 | 南方医科大学 | 一种含取代联苯的黄酮及其应用 |
| CN109438263A (zh) | 2018-11-28 | 2019-03-08 | 南方医科大学 | 一种含取代联苯的萘及其应用 |
| CN109503546A (zh) | 2019-01-10 | 2019-03-22 | 南方医科大学 | 一种间苯二酚二苯甲醚及其应用 |
| CN109776377B (zh) | 2019-02-01 | 2021-08-24 | 沈阳药科大学 | 吲哚啉类化合物及其制备方法和应用 |
| CN109776445B (zh) | 2019-03-28 | 2022-12-06 | 中国药科大学 | 苯并噁二唑类化合物及其制备方法和医药用途 |
| BR112021022659A2 (pt) | 2019-05-15 | 2022-03-29 | Chemocentryx Inc | Compostos triarílicos para o tratamento de doenças pd-l1 |
| CN110200959A (zh) | 2019-05-30 | 2019-09-06 | 天津科技大学 | 一种黄酮类化合物的应用 |
| CN110128415B (zh) | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | 用作免疫调节剂的吲哚啉类化合物及其制备方法 |
| EP3986392A4 (en) | 2019-06-20 | 2023-07-12 | ChemoCentryx, Inc. | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES |
| AU2020368392A1 (en) | 2019-10-16 | 2022-04-21 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| TW202216694A (zh) | 2020-06-23 | 2022-05-01 | 美商卡默森屈有限公司 | 使用雜芳基-聯苯醯胺衍生物治療癌症之方法 |
-
2020
- 2020-10-15 WO PCT/US2020/055672 patent/WO2021076691A1/en unknown
- 2020-10-15 PE PE2022000616A patent/PE20221445A1/es unknown
- 2020-10-15 JP JP2022522680A patent/JP2022551973A/ja active Pending
- 2020-10-15 AU AU2020368393A patent/AU2020368393A1/en active Pending
- 2020-10-15 BR BR112022006018A patent/BR112022006018A2/pt unknown
- 2020-10-15 CN CN202080073061.4A patent/CN114585359A/zh active Pending
- 2020-10-15 CA CA3152329A patent/CA3152329A1/en active Pending
- 2020-10-15 CR CR20220215A patent/CR20220215A/es unknown
- 2020-10-15 EP EP20877065.1A patent/EP4045036A4/en active Pending
- 2020-10-15 US US17/071,077 patent/US11713307B2/en active Active
- 2020-10-15 MX MX2022004451A patent/MX2022004451A/es unknown
- 2020-10-15 KR KR1020227016263A patent/KR20220084119A/ko unknown
- 2020-10-16 TW TW109135946A patent/TW202128651A/zh unknown
-
2022
- 2022-03-23 IL IL291642A patent/IL291642A/en unknown
- 2022-04-13 CO CONC2022/0004723A patent/CO2022004723A2/es unknown
- 2022-04-14 CL CL2022000956A patent/CL2022000956A1/es unknown
- 2022-05-13 EC ECSENADI202238478A patent/ECSP22038478A/es unknown
-
2023
- 2023-06-12 US US18/333,262 patent/US20230322731A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11713307B2 (en) | 2023-08-01 |
| PE20221445A1 (es) | 2022-09-21 |
| US20230322731A1 (en) | 2023-10-12 |
| WO2021076691A1 (en) | 2021-04-22 |
| BR112022006018A2 (pt) | 2022-07-12 |
| IL291642A (en) | 2022-05-01 |
| ECSP22038478A (es) | 2022-06-30 |
| EP4045036A4 (en) | 2023-11-15 |
| CL2022000956A1 (es) | 2023-01-13 |
| CN114585359A (zh) | 2022-06-03 |
| TW202128651A (zh) | 2021-08-01 |
| CO2022004723A2 (es) | 2022-04-29 |
| EP4045036A1 (en) | 2022-08-24 |
| US20210130325A1 (en) | 2021-05-06 |
| CA3152329A1 (en) | 2021-04-22 |
| KR20220084119A (ko) | 2022-06-21 |
| AU2020368393A1 (en) | 2022-04-21 |
| JP2022551973A (ja) | 2022-12-14 |
| MX2022004451A (es) | 2022-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| MX2018005019A (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| MX2019015744A (es) | Composiciones farmaceuticas. | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| MX2019014122A (es) | Formulaciones de dosis fija. | |
| EP3934652A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES | |
| CR20190537A (es) | Inhibidores pirazólicos de magl | |
| PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| MY193740A (en) | "substituted 2,4 diamino-quinoline as new anticancer agents" | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| MX2021002916A (es) | Pirfenidona enriquecida con deuterio y métodos para su uso. | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| GEP20247585B (en) | Furoindazole derivatives | |
| SG10201811574YA (en) | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| WO2021100029A3 (en) | Prodrugs of fulvestrant | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX2021003643A (es) | Derivados de terpenoides y usos de los mismos. | |
| MX2020013389A (es) | Composiciones de terlipresina y usos de las mismas. |